Larry Hanover

After a more than 35-year pursuit, the licensing of a gene therapy product for treating hemophilia may be available within 2 years.

Advancements in gene therapy approaches have opened the door for a glimpse into the future of care for a number of diseases.

Although safety remains a concern with gene therapy, investigators are breaking ground in cell and gene therapy, and many believe that ultimately, a string of cured cancers will follow.